A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects

Not Applicable

Not yet recruiting

• Conditions: Non - Alcoholic Steatohepatitis
• Interventions: Drug: HEC169584 capsule; Drug: placebo

• Registration Number: NCT07099118
• Lead Sponsor: Sunshine Lake Pharma Co., Ltd.

Brief Summary

The safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics study of HEC169584 capsules in healthy subjects .

Detailed Description

This trial adopts a single - center, randomized, double - blind, placebo - controlled, dose - escalation trial design.

This trial is divided into two parts. The first part consists of a single - ascending - dose (SAD) trial and a food - effect (FE) trial. The second part is a multiple - ascending - dose (MAD) tria.

Screening will be conducted within 28 days prior to the first drug administration. After all test results are obtained, inclusion and exclusion criteria will be verified. Eligible subjects will be admitted to the research center one day before drug administration (D - 1). Researchers will assign random numbers to eligible subjects of the same dose group in ascending order according to their screening numbers, and conduct relevant examinations and collect blood, urine, and fecal samples (if necessary) at the time points specified in the protocol.

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-18
• Study First Submitted QC: 2025-07-24
• Last Update Submitted: 2025-07-24
• Study First Posted: 2025-08-01
• Last Update Posted: 2025-08-01
• Study Start: 2025-08-14
• Primary Completion: 2026-12-30
• Study Completion: 2027-03-06

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

1. Subjects should understand and abide by the research procedures, volunteer to participate, and sign the informed consent form.
2. When signing the informed consent form, subjects should be between 18 and 45 years old (including the boundary values), and both genders are eligible.
3. Male subjects should weigh ≥ 50.0 kg, and female subjects should weigh ≥ 45.0 kg. For the single - dose trial, the body mass index [BMI = weight (kg) / height² (m²)] should be within the range of 18.0 - 28.0 kg/m² (including the boundary values). For the multiple - dose trial, the BMI should be within the range of 18.0 - 30.0 kg/m² (including the boundary values).
4. Subjects enrolled in the MAD (Multiple - Ascending - Dose) trial should also meet the requirement that 2.6 mmol/L (100 mg/dL) ≤ LDL - C < 4.1 mmol/L (160 mg/dL).
5. The results of vital signs, physical examinations, clinical laboratory tests, electrocardiograms, chest X - rays (posteroanterior view), abdominal color Doppler ultrasounds, etc. should be normal, or if judged as abnormal by the investigator, they should be of no clinical significance.
6. Subjects (including their partners) should voluntarily adopt effective contraceptive measures from the screening stage until 3 months after the last drug administration, and should have no plans for sperm or egg donation.

Exclusion Criteria

1. Subjects had clinically significant diseases as follows (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immunological, mental, or cardiovascular and cerebrovascular diseases) before screening.
2. Subjects with allergic constitution (allergic to multiple drugs or foods).
3. Subjects who smoked more than 5 cigarettes per day on average within 3 months before screening, or smoked within 48 hours before taking the investigational product, or could not stop using any tobacco products during the trial.
4. Subjects had a history of dysphagia before screening, or had a history of gastrointestinal, hepatic, or renal diseases or surgeries that potentially affect the absorption, distribution, metabolism, and excretion of the investigational product (except uncomplicated appendectomy and hernia repair).
5. Subjects had a history of alcoholism within 1 year before screening (consuming 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine), or had a positive alcohol breath test during the screening period.
6. Subjects had a history of drug abuse or used drugs within 2 years before screening, or had a positive urine drug screening during the screening period.
7. Subjects donated blood or lost blood ≥ 400 mL within 3 months before screening, or planned to donate blood within 1 month after the end of the trial.
8. Subjects had a history of thyroid diseases, or the thyroid - stimulating hormone (TSH) index in the thyroid function test during the screening period was beyond the normal range.
9. Subjects had a corrected QT interval (QTcF = QT/RR0.33 calculated by the Fridericia formula) of the 12 - lead electrocardiogram > 450 ms during screening.
10. Subjects had a glomerular filtration rate < 90 mL/min (the glomerular filtration rate is calculated using the simplified MDRD formula: for men, eGFR = 186 × creatinine (mg/dL)-1.154 × age - 0.203; for women, eGFR = 186 × creatinine (mg/dL)-1.154 × age - 0.203 × 0.742). Note: The unit of creatinine in the formula is mg/dL. When calculating, the creatinine result in μmol/L needs to be converted to mg/dL, and 1 μmol/L = 0.01131 mg/dL.
11. Subjects received vaccination within 1 month before screening, or planned to receive vaccination during the trial.
12. Subjects took inhibitors and/or inducers of CYP3A4, CYP2C8, P - gp, or BCRP within 4 weeks before screening.
13. Subjects took any prescription drugs, over - the - counter drugs, any vitamin products, or Chinese herbal medicines within 14 days before screening.
14. Subjects consumed foods or beverages containing chocolate, caffeine, xanthine, alcohol, or grapefruit within 48 hours before the first drug administration.
15. Subjects developed an acute illness or had concomitant medications from the screening stage to before the first drug administration.
16. Subjects had a history of fainting at the sight of needles or blood, could not tolerate intravenous puncture for blood collection, or had difficulty in blood collection.
17. Lactating or pregnant women, or women of child - bearing potential with a positive pregnancy test.
18. Subjects participated in other clinical trials within 3 months before screening (if the subject withdrew from the study before treatment, that is, was not randomized or did not receive treatment, they can be enrolled in this study).
19. Subjects tested positive for any one of hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or treponema pallidum antibody.
20. Subjects had special dietary requirements and could not accept the unified diet.
21. Subjects with other factors that, in the investigator's opinion, make them inappropriate to participate in this trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dose group-1	HEC169584 capsule	On day1 subjects will take the experiment drug on an empty stomach with 240ml warm water.
Dose group-2	placebo	Single ascending-dose study: on day1 subjects will take the 30 mg experiment drug on an empty stomach with 240ml warm water ;
Dose group-7	placebo	Single ascending-dose study: on day1, subjects will take 600 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-8	HEC169584 capsule	Arm Description: Single ascending-dose study: on day1, subjects will take 800 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-9	HEC169584 capsule	Multiple ascending-dose study: Day1-Day14 , subjects will take 70 mg, QD experiment drug or placeble with 240ml warm water on an empty stomach.
Dose group-2	HEC169584 capsule	Single ascending-dose study: on day1 subjects will take the 30 mg experiment drug on an empty stomach with 240ml warm water ;
Dose group-6	HEC169584 capsule	Single ascending-dose study: on day1, subjects will take 450 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-7	HEC169584 capsule	Single ascending-dose study: on day1, subjects will take 600 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-10	placebo	Multiple ascending-dose study: Day1-Day14 , subjects will take 150 mg, QD experiment drug or placeble with 240ml warm water on an empty stomach.
Dose group-3	HEC169584 capsule	Single ascending-dose study: on day1, subjects will take 70 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-3	placebo	Single ascending-dose study: on day1, subjects will take 70 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-4	HEC169584 capsule	Single ascending-dose study: on day1, subjects will take 150 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-5	placebo	Single ascending-dose study: on day1, subjects will take 300 mg the experiment drug or placeble on an empty stomach with 240ml warm water. Subjects also need to take experiment drug after high - fat and high - calorie meals on day 15
Dose group-6	placebo	Single ascending-dose study: on day1, subjects will take 450 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-4	placebo	Single ascending-dose study: on day1, subjects will take 150 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-5	HEC169584 capsule	Single ascending-dose study: on day1, subjects will take 300 mg the experiment drug or placeble on an empty stomach with 240ml warm water. Subjects also need to take experiment drug after high - fat and high - calorie meals on day 15
Dose group-8	placebo	Arm Description: Single ascending-dose study: on day1, subjects will take 800 mg the experiment drug or placeble on an empty stomach with 240ml warm water.
Dose group-10	HEC169584 capsule	Multiple ascending-dose study: Day1-Day14 , subjects will take 150 mg, QD experiment drug or placeble with 240ml warm water on an empty stomach.
Dose group-9	placebo	Multiple ascending-dose study: Day1-Day14 , subjects will take 70 mg, QD experiment drug or placeble with 240ml warm water on an empty stomach.
Dose group-11	HEC169584 capsule	Multiple ascending-dose study: Day1-Day14 , subjects will take 300 mg, QD experiment drug or placeble with 240ml warm water on an empty stomach.
Dose group-11	placebo	Multiple ascending-dose study: Day1-Day14 , subjects will take 300 mg, QD experiment drug or placeble with 240ml warm water on an empty stomach.

Primary Outcome Measures

Name	Time	Method
Adverse event	up to 27 days	Evaluate the safety and tolerability of single/multiple administrations of HEC169584 capsules in healthy subjects.

Secondary Outcome Measures

Name	Time	Method
PK parameters - AUC0-∞	up to 48 hours	area under the concentration versus time curve (AUC) from time zero to infinity
PK parameters - AUC0-t	up to 48 hours	Area under the concentration versus time curve (AUC) from time zero to 48 h (AUC0-48 )
PK parameters - Cmax	up to 48 hours	Maximum Plasma Concentration ( Cmax)
PK parameters -Vz/F	up to 48 hours	Apparent volume of distribution(Vz/F)
PK parameters -The Accumulation Ratio(R)	up to 15 days	The Accumulation Ratio(R)
PK parameters -Food Effect on the AUC	up to 48 hours	The geometric mean percentage of AUC between post - meal administration and fasting administration
PK parameters - tmax	up to 48 hours	Time to peak(tmax)
PK parameters - t½	up to 48 hours	Apparent terminal elimination half-life(t½)
PK parameters -MRT	up to 48 hours	The Mean Residence Time#(MRT)
PK parameters -CL/F	up to 48 hours	The Apparent Clearance (CL/F)
PK parameters -Food Effect on the Cmax	up to 48 hours	The geometric mean percentage of Cmax between post - meal administration and fasting administration
The pharmacodynamics of HEC169584 capsules	Time Frame: up to 28 days	The pharmacodynamics of HEC169584 capsules was preliminarily explored through SHBG(Sex Hormone - Binding Globulin) and Fasting blood lipid.

Trial Locations

Locations (1)

No. 49, Huayuan North Road, Haidian District, Beijing Municipality; 🇨🇳 Beijing, Beijing, China